Pharvaris (NASDAQ:PHVS) Hits New 1-Year High – Here’s Why

Pharvaris N.V. (NASDAQ:PHVS)’s share price reached a new 52-week high on Wednesday . The company traded as high as $33.50 and last traded at $33.3850, with a volume of 81367 shares traded. The stock had previously closed at $31.46.

Wall Street Analyst Weigh In

PHVS has been the topic of a number of research reports. Wolfe Research began coverage on Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective on the stock. UBS Group set a $74.00 price target on shares of Pharvaris in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Royal Bank Of Canada decreased their target price on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.18.

Pharvaris Price Performance

The company’s 50 day moving average price is $29.91 and its 200 day moving average price is $27.71. The firm has a market capitalization of $2.15 billion, a P/E ratio of -10.31 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, research analysts anticipate that Pharvaris N.V. will post -3.22 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Anna Nijdam sold 2,670 shares of Pharvaris stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $30.87, for a total transaction of $82,422.90. Following the transaction, the insider directly owned 46,275 shares of the company’s stock, valued at $1,428,509.25. This trade represents a 5.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Elisabeth Bjork sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $29.32, for a total transaction of $293,200.00. Following the completion of the transaction, the director directly owned 15,167 shares of the company’s stock, valued at $444,696.44. This trade represents a 39.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 214,909 shares of company stock worth $6,421,745 over the last quarter. Insiders own 11.84% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. General Atlantic L.P. increased its position in shares of Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC lifted its position in Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after acquiring an additional 368,000 shares in the last quarter. venBio Partners LLC boosted its stake in Pharvaris by 8.2% in the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after purchasing an additional 350,000 shares during the period. Deerfield Management Company L.P. increased its holdings in Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP raised its stake in shares of Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after purchasing an additional 507,043 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.